PIQ 주식 개요 프로테오믹스 인터내셔널 래버러토리즈는 호주, 뉴질랜드, 미국, 유럽, 인도 및 동남아시아에서 프로테오믹스 분야에 중점을 둔 의료 기술 회사로 운영되고 있습니다. 자세한 내용
보상 위험 분석 + 1 더 많은 위험
모든 위험 점검 보기 생각, 링크 및 회사 내러티브를 캡처하세요.
Proteomics International Laboratories Ltd 경쟁사 가격 내역 및 성능
다음에 대한 주가 최고가, 최저가 및 변동 요약 Proteomics International Laboratories 과거 주가 현재 주가 AU$0.62 52주 최고치 AU$1.39 52주 최저치 AU$0.55 베타 0.49 1개월 변경 -8.15% 3개월 변경 사항 -6.06% 1년 변경 사항 -27.06% 3년 변화 -45.13% 5년 변화 121.43% IPO 이후 변화 169.57%
최근 뉴스 및 업데이트
New major risk - Financial position Sep 11
Full year 2024 earnings released: AU$0.051 loss per share (vs AU$0.053 loss in FY 2023) Aug 23
Proteomics International Laboratories Ltd, Annual General Meeting, Nov 01, 2024 Aug 23
Proteomics International Laboratories Ltd Announces Resignation of Robyn Elliott as Non-Executive Director Aug 12
No longer forecast to breakeven Jun 17
New minor risk - Profitability Feb 24 더 많은 업데이트 보기
New major risk - Financial position Sep 11
Full year 2024 earnings released: AU$0.051 loss per share (vs AU$0.053 loss in FY 2023) Aug 23
Proteomics International Laboratories Ltd, Annual General Meeting, Nov 01, 2024 Aug 23
Proteomics International Laboratories Ltd Announces Resignation of Robyn Elliott as Non-Executive Director Aug 12
No longer forecast to breakeven Jun 17
New minor risk - Profitability Feb 24 Proteomics International Laboratories Limited has filed a Follow-on Equity Offering in the amount of AUD 6.504 million. Proteomics International Laboratories Limited has filed a Follow-on Equity Offering. Jan 23
New minor risk - Share price stability Oct 04
New major risk - Financial position Oct 02
High number of new and inexperienced directors Sep 29
Proteomics International Laboratories Limited, Annual General Meeting, Nov 23, 2023 Aug 22
Full year 2023 earnings released: AU$0.05 loss per share (vs AU$0.047 loss in FY 2022) Aug 22
First half 2023 earnings released: AU$0.03 loss per share (vs AU$0.03 loss in 1H 2022) Mar 05
Proteomics International Laboratories Ltd Announces the Achievement of a Major Milestone in the Commercialisation of the PromarkerD Predictive Test for Diabetic Kidney Disease with the Approval of a New Dedicated CPT Proprietary Laboratory Analyses (PLA) Code for the Test in the United States Jan 03
High number of new and inexperienced directors Nov 16
Proteomics International Laboratories Ltd Secures A Patent in Hong Kong for PromarkerD, First Predictive Diagnostic Test for Diabetic Kidney Disease Nov 12
Proteomics International Laboratories Limited Announces Its Prototype Diagnostic Test for Oesophageal Adenocarcinoma Demonstrates Strong Diagnostic Performance Sep 28
Full year 2022 earnings released: AU$0.05 loss per share (vs AU$0.028 loss in FY 2021) Aug 31
Proteomics International Laboratories Limited, Annual General Meeting, Nov 24, 2022 Aug 30 Proteomics International Laboratories Limited announced that it expects to receive AUD 7.9985 million in funding Aug 16
Proteomics International Laboratories Limited Announces Clinical Utility Study Demonstrates PromarkerD Test Offers Improved Treatment Options for Doctors in the Fight Against Diabetic Kidney Disease
Proteomics International Laboratories Limited Completes the Initial Analysis of Its Endometriosis Clinical Validation Study Aimed At Diagnosing the Gynaecological Condition Using A Simple Blood Test Jul 01
Proteomics International Laboratories Limited Successfully Produce A Pilot Batch of PromarkerD Test Components with Specialist Immunoassay Manufacturer Biotem Jun 16
Proteomics International Laboratories Limited Study Shows PromarkerD also Predicts Late-Stage Renal Issues Jun 07
Proteomics International Laboratories Limited Announces PromarkerD Registration Submitted to the TGA Jun 04
High number of new and inexperienced directors Jun 01
High number of new and inexperienced directors May 02
Proteomics International Laboratories Limited Announces New Clinical Advisory Board Apr 12
First half 2022 earnings: Revenues and EPS in line with analyst expectations Mar 02
Proteomics International Laboratories Limited Completes Pre-Assessment Phase of PromarkerD Feb 22
Proteomics International Laboratories Limited Identifies Novel Biomarkers for Asthma and COPD Feb 07
Independent Non-Executive Chairman Terry Sweet has left the company Nov 29
Independent Non-Executive Chairman Terry Sweet has left the company Nov 29
Independent Non-Executive Chairman Terry Sweet has left the company Nov 29
Independent Non-Executive Chairman Terry Sweet has left the company Nov 29
Independent Non-Executive Chairman Terry Sweet has left the company Nov 29
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 28
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 27
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Independent Non-Executive Chairman Terry Sweet has left the company Nov 26
Full year 2021 earnings released: AU$0.03 loss per share (vs AU$0.02 loss in FY 2020) Sep 01
Proteomics International Laboratories Ltd Announces PromarkerD Test Jun 25
Proteomics International Laboratories Ltd Announces Results of an Economic Health Benefit Study for PromarkerD May 15
Proteomics International Laboratories Limited Files a 513(g) Submission to the United States Food and Drug Administration for its PromarkerD Test for Diabetic Kidney Disease Apr 29
First half 2021 earnings released: AU$0.02 loss per share (vs AU$0.01 loss in 1H 2020) Feb 26 주주 수익률 PIQ AU Life Sciences AU 마켓 7D -6.8% 1.1% -2.7% 1Y -27.1% 13.8% 6.5%
전체 주주 수익률 보기
수익률 대 산업: PIQ 지난 1년 동안 13.8 %를 반환한 Australian Life Sciences 업계보다 저조한 성과를 냈습니다.
수익률 대 시장: PIQ 지난 1년 동안 6.5 %를 반환한 Australian 시장보다 저조한 성과를 냈습니다.
가격 변동성 Is PIQ's price volatile compared to industry and market? PIQ volatility PIQ Average Weekly Movement 8.1% Life Sciences Industry Average Movement 8.9% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.8% 10% least volatile stocks in AU Market 3.1%
안정적인 주가: PIQ 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.
시간에 따른 변동성: PIQ 의 주간 변동성 ( 8% )은 지난 1년 동안 안정적인 모습을 보였습니다.
회사 소개 프로테오믹스 인터내셔널 래버러토리즈는 호주, 뉴질랜드, 미국, 유럽, 인도, 동남아시아에서 프로테오믹스 분야에 중점을 둔 의료 기술 회사로 운영되고 있습니다. 당뇨병성 신장 질환(DKD)을 예측하는 단백질 기반 진단 혈액 검사 PromarkerD를 제공합니다. 개발 중인 제품으로는 자궁내막증 진단 임상 검증 단계를 완료한 프로마커엔도, 식도암 진단 임상 검증 시험을 완료한 프로마커에소, 산화 스트레스 치료 임상 검증 단계를 완료한 옥시디엑스(2-tag) 등이 있습니다.
자세히 보기 Proteomics International Laboratories Ltd 기본 사항 요약 Proteomics International Laboratories 의 수익과 매출은 시가총액과 어떻게 비교하나요? PIQ 기본 통계 시가총액 AU$83.84m 수익(TTM ) -AU$6.38m 수익(TTM ) AU$3.28m
수익 및 수익 최신 수익 보고서의 주요 수익성 통계(TTM) PIQ 손익 계산서(TTM ) 수익 AU$3.28m 수익 비용 AU$2.02m 총 이익 AU$1.26m 기타 비용 AU$7.64m 수익 -AU$6.38m
주당 순이익(EPS) -0.049 총 마진 38.49% 순이익 마진 -194.62% 부채/자본 비율 0%
PIQ 의 장기적인 성과는 어땠나요?
과거 실적 및 비교 보기
기업 분석 및 재무 데이터 현황 데이터 마지막 업데이트(UTC 시간) 기업 분석 2024/12/21 15:46 장 마감 주가 2024/12/20 00:00 수익 2024/06/30 연간 수익 2024/06/30
데이터 소스 기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.
패키지 데이터 기간 미국 소스 예시 * 회사 재무 10년 애널리스트 컨센서스 추정치 +3년 시장 가격 30년 소유권 10년 관리 10년 주요 개발 사항 10년
* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.
명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.
분석 모델 및 눈송이 이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.
Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.
산업 및 부문 메트릭 업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.
애널리스트 출처 Proteomics International Laboratories Ltd 1 애널리스트 중 1 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.
분석가 교육기관 Iain Wilkie Morgans Financial Limited
0 더 많은 분석가 보기 
